Gut Liver.  2021 Jan;15(1):70-76. 10.5009/gnl19273.

Expression of Chemokine CCL28 in Ulcerative Colitis Patients

• Lee DS
• Lee KL
• Jeong JB
• Shin S
• Kim SH
• Kim JW

• KMID: 2513677
• DOI: http://doi.org/10.5009/gnl19273

Abstract

Background/Aims
Ulcerative colitis (UC) is an inflammatory bowel disease for which new serological markers are required. The purpose of this study was to assess the role of the mucosaassociated epithelial chemokine CCL28 in UC.
Methods
The study included 50 patients; of these, 25 were patients with UC, and 25 were healthy controls. The levels of serum CCL28 were analyzed using enzyme-linked immunosorbent assay. CCL28 expression was analyzed by immunohistochemistry (IHC) in 15 representative colon tissues biopsied based on disease activity (UC patients with severe activity, five samples;UC patients with mild activity, five samples; healthy controls, five samples).
Results
The serum CCL28 levels were remarkably higher (p<0.05) in patients with UC (median, 235.7 pg/mL; IQR, 63.8 to 117.2 pg/mL) than in healthy controls (median, 48.9, pg/mL; IQR, 35.9 to 42.0 pg/mL). However, there was no significant difference in serum CCL28 according to disease extent or activity. In contrast, IHC analysis revealed a significant difference in CCL28 consistent with disease status, disease extent, and disease activity.
Conclusions
CCL28 could be useful for diagnosing UC. However, further validations of CCL28 on disease activity and severity are needed.

Keyword

Colitis; ulcerative; CCL28; Serologic markers; Biomarker; Disease activity